SCHEMBL22499298

SCHEMBL22499298

C#Cc1cccc2[nH]nc(N)c12

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K1 Q02750 2/20 0.70
GAA P10253 2/20 0.61
PDPK1 O15530 3/20 0.56
KDR P35968 8/20 0.50
KIT P10721 4/20 0.50
FLT3 P36888 3/20 0.50
ABL1 P00519 5/20 0.47
ROCK1 Q13464 4/20 0.47
JAK2 O60674 4/20 0.47
LCK P06239 3/20 0.47
CSF1R P07333 3/20 0.47
FGFR1 P11362 3/20 0.47
PRKACA P17612 3/20 0.47
CDK5 Q00535 3/20 0.47
CLK4 Q9HAZ1 2/20 0.47
PLK4 O00444 2/20 0.47
AURKA O14965 2/20 0.47
CDK1 P06493 2/20 0.47
LYN P07948 2/20 0.47
SRC P12931 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL186113 0.82 MAP2K1 (1.00) MAP2K1GAAPDPK1KDRKIT
SCHEMBL17424248 0.77 KDR (0.66) MAP2K1GAAPDPK1KDRKIT
SCHEMBL186280 0.76 GAA (1.00) MAP2K1GAAPDPK1KDRKIT
SCHEMBL30065304 0.75 PDPK1 (0.66) MAP2K1GAAPDPK1KDRKIT
SCHEMBL628649 0.75 PDPK1 (0.66) MAP2K1GAAPDPK1KDRKIT
SCHEMBL17409467 0.73 KDR (0.62) MAP2K1GAAPDPK1KDRKIT
SCHEMBL12928484 0.72 PDPK1 (0.61) MAP2K1GAAPDPK1KDRKIT
SCHEMBL185907 0.72 GAA (0.61) MAP2K1GAAPDPK1KDRKIT
SCHEMBL7736987 0.72 PDPK1 (0.61) MAP2K1GAAPDPK1KDRKIT
SCHEMBL569660 0.72 GAA (0.61) MAP2K1GAAPDPK1KDRKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388577-A1 METTL3 INHIBITORY COMPOUNDS STORM THERAPEUTICS LTD (GB) 2025-12-25 US disclosed
US-12358915-B2 METTL3 inhibitory compounds STORM Therapeutics Ltd. (GB) 2025-07-15 US disclosed
US-20230085408-A1 METTL3 INHIBITORY COMPOUNDS STORM THERAPEUTICS LIMITED (GB) 2023-03-16 US disclosed
EP-3946618-A1 METTL3 INHIBITORY COMPOUNDS Storm Therapeutics Ltd (GB) 2022-02-09 EP disclosed
CN-113905787-A METTL3 inhibiting compounds 斯托姆治疗有限公司 2022-01-07 CN disclosed
WO-2020201773-A1 METTL3 INHIBITORY COMPOUNDS STORM THERAPEUTICS LTD (GB) 2020-10-08 WO disclosed
WO-2020201773-A1 METTL3 INHIBITORY COMPOUNDS STORM THERAPEUTICS LTD (GB) 2020-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12358915-B2 METTL3 inhibitory compounds METTL3, METTL16, DIMT1 MAP2K1 3917/4885GAA 769/4885PDPK1 3854/4885
US-20250388577-A1 METTL3 INHIBITORY COMPOUNDS METTL3, RNMT, TPMT MAP2K1 4440/4885GAA 2030/4885PDPK1 4728/4885
US-20230085408-A1 METTL3 INHIBITORY COMPOUNDS METTL3, METTL16, DIMT1 MAP2K1 3917/4885GAA 769/4885PDPK1 3854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.